<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C754D612-4D8B-42CB-922C-07E7F5BE4B49"><gtr:id>C754D612-4D8B-42CB-922C-07E7F5BE4B49</gtr:id><gtr:name>Washington University in St. Louis</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9456E24E-2809-4A14-9144-41F1CFC30AD9"><gtr:id>9456E24E-2809-4A14-9144-41F1CFC30AD9</gtr:id><gtr:name>King Edward Memorial Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BF06ABFB-9547-484C-84F9-4110ED8759B7"><gtr:id>BF06ABFB-9547-484C-84F9-4110ED8759B7</gtr:id><gtr:name>Manchester University NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Central Manchester University Hospitals NHS Foundation Trust,Manchester Royal Infirmary,Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9WL</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DDD14154-81FB-417E-81AA-AAEA066ECA04"><gtr:id>DDD14154-81FB-417E-81AA-AAEA066ECA04</gtr:id><gtr:name>The Wellcome Trust  Sanger Institute</gtr:name><gtr:address><gtr:line1>Wellcome Trust Genome Campus</gtr:line1><gtr:line2>Hinxton</gtr:line2><gtr:postCode>CB10 1SA</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1E3015FF-23BB-4B73-8C80-84C53F33B745"><gtr:id>1E3015FF-23BB-4B73-8C80-84C53F33B745</gtr:id><gtr:name>Hospital for Sick Children, Toronto</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/244DB29F-915F-49C7-A968-87822A13AD3C"><gtr:id>244DB29F-915F-49C7-A968-87822A13AD3C</gtr:id><gtr:name>The Jackson Laboratory</gtr:name><gtr:address><gtr:line1>600 Main Street</gtr:line1><gtr:line2>Bar Harbor</gtr:line2><gtr:postCode>04609</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7F06A235-D83F-4EDF-A8A3-9216E21C9752"><gtr:id>7F06A235-D83F-4EDF-A8A3-9216E21C9752</gtr:id><gtr:name>Charles University</gtr:name><gtr:address><gtr:line1>Ke Karlovu 3</gtr:line1><gtr:postCode>121 16 Pra</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Czech Republic</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C85FEE8F-4918-4146-B2FF-E4A55389BF80"><gtr:id>C85FEE8F-4918-4146-B2FF-E4A55389BF80</gtr:id><gtr:name>Oregon Health and Science University</gtr:name><gtr:address><gtr:line1>Oregon Health and Science University</gtr:line1><gtr:line4>Portland</gtr:line4><gtr:line5>OR 97201-30</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2C711771-B8F6-4CDF-9AC3-9FAB317463D9"><gtr:id>2C711771-B8F6-4CDF-9AC3-9FAB317463D9</gtr:id><gtr:name>University of Cape Town</gtr:name><gtr:address><gtr:line1>Private Bag</gtr:line1><gtr:line2>Rondebosch</gtr:line2><gtr:postCode>7700</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>South Africa</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/13AF0851-E73B-4363-9B18-BF1D5AF34257"><gtr:id>13AF0851-E73B-4363-9B18-BF1D5AF34257</gtr:id><gtr:name>Imagine Institute</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DAEB2B76-3CE2-4F67-BE52-859227BD2B8F"><gtr:id>DAEB2B76-3CE2-4F67-BE52-859227BD2B8F</gtr:id><gtr:name>Great Ormond Street Hospital (GOSH)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FC20619C-24CC-4562-8F2A-B1C34FB19874"><gtr:id>FC20619C-24CC-4562-8F2A-B1C34FB19874</gtr:id><gtr:name>University Medical Centre Nijmegen</gtr:name><gtr:address><gtr:line1>Uinversity Medical Centre Nijmegen</gtr:line1><gtr:line2>PO Box 9101</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FEF0A749-B120-4F09-B8E8-01CFCDFC0A2F"><gtr:id>FEF0A749-B120-4F09-B8E8-01CFCDFC0A2F</gtr:id><gtr:name>Baylor College of Medicine</gtr:name><gtr:address><gtr:line1>Baylor College of Medicine</gtr:line1><gtr:line2>Texas Medical Center</gtr:line2><gtr:line4>Houston</gtr:line4><gtr:line5>Texas</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/696A0A2F-736F-4546-B0F4-F347F0F8488E"><gtr:id>696A0A2F-736F-4546-B0F4-F347F0F8488E</gtr:id><gtr:name>Freeman Hospital</gtr:name><gtr:address><gtr:line1>Liver and Renal Transplant Unit
Freeman Hospital
Freeman Road
High Heaton</gtr:line1><gtr:city>Newcastle Upon Tyne</gtr:city><gtr:postCode>NE7 7DN</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F5914C2A-6AE8-4A26-ACA8-99C3D6D87514"><gtr:id>F5914C2A-6AE8-4A26-ACA8-99C3D6D87514</gtr:id><gtr:name>University of Melbourne</gtr:name><gtr:address><gtr:line1>University of Melbourne</gtr:line1><gtr:line2>Melbourne Research Office</gtr:line2><gtr:line3>Parkville</gtr:line3><gtr:line4>Melbourne</gtr:line4><gtr:line5>Victoria</gtr:line5><gtr:postCode>3010</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2E8E7A84-3BC7-4739-986D-C05FC31789B8"><gtr:id>2E8E7A84-3BC7-4739-986D-C05FC31789B8</gtr:id><gtr:name>Charit? - University of Medicine Berlin</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F34AC300-EA0B-49AC-9DE8-DF4287E54B4F"><gtr:id>F34AC300-EA0B-49AC-9DE8-DF4287E54B4F</gtr:id><gtr:name>The Garvan Institute for Medical Research</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Physiology Anatomy and Genetics</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C754D612-4D8B-42CB-922C-07E7F5BE4B49"><gtr:id>C754D612-4D8B-42CB-922C-07E7F5BE4B49</gtr:id><gtr:name>Washington University in St. Louis</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9456E24E-2809-4A14-9144-41F1CFC30AD9"><gtr:id>9456E24E-2809-4A14-9144-41F1CFC30AD9</gtr:id><gtr:name>King Edward Memorial Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BF06ABFB-9547-484C-84F9-4110ED8759B7"><gtr:id>BF06ABFB-9547-484C-84F9-4110ED8759B7</gtr:id><gtr:name>Manchester University NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Central Manchester University Hospitals NHS Foundation Trust,Manchester Royal Infirmary,Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9WL</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DDD14154-81FB-417E-81AA-AAEA066ECA04"><gtr:id>DDD14154-81FB-417E-81AA-AAEA066ECA04</gtr:id><gtr:name>The Wellcome Trust  Sanger Institute</gtr:name><gtr:address><gtr:line1>Wellcome Trust Genome Campus</gtr:line1><gtr:line2>Hinxton</gtr:line2><gtr:postCode>CB10 1SA</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1E3015FF-23BB-4B73-8C80-84C53F33B745"><gtr:id>1E3015FF-23BB-4B73-8C80-84C53F33B745</gtr:id><gtr:name>Hospital for Sick Children, Toronto</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/244DB29F-915F-49C7-A968-87822A13AD3C"><gtr:id>244DB29F-915F-49C7-A968-87822A13AD3C</gtr:id><gtr:name>The Jackson Laboratory</gtr:name><gtr:address><gtr:line1>600 Main Street</gtr:line1><gtr:line2>Bar Harbor</gtr:line2><gtr:postCode>04609</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7F06A235-D83F-4EDF-A8A3-9216E21C9752"><gtr:id>7F06A235-D83F-4EDF-A8A3-9216E21C9752</gtr:id><gtr:name>Charles University</gtr:name><gtr:address><gtr:line1>Ke Karlovu 3</gtr:line1><gtr:postCode>121 16 Pra</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Czech Republic</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C85FEE8F-4918-4146-B2FF-E4A55389BF80"><gtr:id>C85FEE8F-4918-4146-B2FF-E4A55389BF80</gtr:id><gtr:name>Oregon Health and Science University</gtr:name><gtr:address><gtr:line1>Oregon Health and Science University</gtr:line1><gtr:line4>Portland</gtr:line4><gtr:line5>OR 97201-30</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2C711771-B8F6-4CDF-9AC3-9FAB317463D9"><gtr:id>2C711771-B8F6-4CDF-9AC3-9FAB317463D9</gtr:id><gtr:name>University of Cape Town</gtr:name><gtr:address><gtr:line1>Private Bag</gtr:line1><gtr:line2>Rondebosch</gtr:line2><gtr:postCode>7700</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>South Africa</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/13AF0851-E73B-4363-9B18-BF1D5AF34257"><gtr:id>13AF0851-E73B-4363-9B18-BF1D5AF34257</gtr:id><gtr:name>Imagine Institute</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DAEB2B76-3CE2-4F67-BE52-859227BD2B8F"><gtr:id>DAEB2B76-3CE2-4F67-BE52-859227BD2B8F</gtr:id><gtr:name>Great Ormond Street Hospital (GOSH)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FC20619C-24CC-4562-8F2A-B1C34FB19874"><gtr:id>FC20619C-24CC-4562-8F2A-B1C34FB19874</gtr:id><gtr:name>University Medical Centre Nijmegen</gtr:name><gtr:address><gtr:line1>Uinversity Medical Centre Nijmegen</gtr:line1><gtr:line2>PO Box 9101</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FEF0A749-B120-4F09-B8E8-01CFCDFC0A2F"><gtr:id>FEF0A749-B120-4F09-B8E8-01CFCDFC0A2F</gtr:id><gtr:name>Baylor College of Medicine</gtr:name><gtr:address><gtr:line1>Baylor College of Medicine</gtr:line1><gtr:line2>Texas Medical Center</gtr:line2><gtr:line4>Houston</gtr:line4><gtr:line5>Texas</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/696A0A2F-736F-4546-B0F4-F347F0F8488E"><gtr:id>696A0A2F-736F-4546-B0F4-F347F0F8488E</gtr:id><gtr:name>Freeman Hospital</gtr:name><gtr:address><gtr:line1>Liver and Renal Transplant Unit
Freeman Hospital
Freeman Road
High Heaton</gtr:line1><gtr:city>Newcastle Upon Tyne</gtr:city><gtr:postCode>NE7 7DN</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F5914C2A-6AE8-4A26-ACA8-99C3D6D87514"><gtr:id>F5914C2A-6AE8-4A26-ACA8-99C3D6D87514</gtr:id><gtr:name>University of Melbourne</gtr:name><gtr:address><gtr:line1>University of Melbourne</gtr:line1><gtr:line2>Melbourne Research Office</gtr:line2><gtr:line3>Parkville</gtr:line3><gtr:line4>Melbourne</gtr:line4><gtr:line5>Victoria</gtr:line5><gtr:postCode>3010</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2E8E7A84-3BC7-4739-986D-C05FC31789B8"><gtr:id>2E8E7A84-3BC7-4739-986D-C05FC31789B8</gtr:id><gtr:name>Charit? - University of Medicine Berlin</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F34AC300-EA0B-49AC-9DE8-DF4287E54B4F"><gtr:id>F34AC300-EA0B-49AC-9DE8-DF4287E54B4F</gtr:id><gtr:name>The Garvan Institute for Medical Research</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/B742EBC0-45FE-4A15-AD54-A9726F252787"><gtr:id>B742EBC0-45FE-4A15-AD54-A9726F252787</gtr:id><gtr:firstName>Christoffer</gtr:firstName><gtr:surname>Nellaker</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FM014568%2F1"><gtr:id>A398A9B6-708D-4737-A582-2548471FCC95</gtr:id><gtr:title>Developing diagnostic methods for clinical genetics - phenotyping from faces in photos.</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>MR/M014568/1</gtr:grantReference><gtr:abstractText>I am leading research that will help clinicians to diagnose rare diseases using automated computer analysis of photos. 

Rare diseases are numerous - so much so that as a group they are very common. One person in 17 has a rare genetic disorder, but most fail to receive a genetic diagnosis. Diagnosing the genetic cause of a disorder, even when there are only a handful of cases in the world, represents the first of many steps in finding effective treatments. Even though new genetic tests promise to assist in diagnosing some of these patients, the tests are expensive and currently only available to a few people in the wealthiest countries.

For the past 65 years expert clinical doctors have been matching a diagnosis to patients based on facial features and follow up clinical tests. We are developing algorithms through which a computer will learn and apply these skills objectively. 

Identifying patients with the same genetic disorders allows comparisons to be made between them. In turn, this can improve estimates of how the disease might progress and allow direct therapeutic benefits, for instance by showing which symptoms are caused by the genetic disorder and which symptoms might be caused by other clinical issues that can be treated.

Using the latest research in computer vision and machine learning the algorithm automatically analyses patient photographs and finds their place in &amp;quot;Clinical Face Phenotype Space&amp;quot; (CFPS). Patients that share a specific dysmorphic disease or syndrome, will cluster together in CFPS. The CFPS model is created and shaped using ordinary, family album photos and accounts for variations between images that are not disease relevant (such as lighting, image quality, background, pose, age, gender, ethnicity, and facial expression).

In the present application I seek funding to develop methods for clinical geneticists to query CFPS for clinically relevant information. The work will develop means by which a patient's similarity to other patient groups can be visualised, explored and tested through robust statistical modelling. 

Furthermore it will make it possible to overlay a patient's DNA with CFPS to identify disease causing mutations. This will improve our understanding of how rare diseases disrupt the normal functioning of the body, and in turn influence decisions in treatment strategies.

A clinician should, in future, be able to take a smartphone picture of a patient and query CFPS to quickly find out which genetic disease the person might have. For diseases unknown to medical science, CFPS will find if there are any other patients around the world that might have the same disease.

CFPS will learn from our faces to help diagnose rare diseases.</gtr:abstractText><gtr:technicalSummary>Aim 1. Enable complete phenotype descriptions from photos for clinicians. I will adapt existing computer vision and machine learning methods for the specific purpose of obtaining phenotype descriptions. CFPS already performs exceptionally well given the limited information that it exploits thus far. Developing the accuracy of craniofacial point annotations and feature descriptors for capturing phenotype characteristics, inferring 3D orientation from 2D images, and applying machine learning approaches will ensure that CFPS reaches its full potential. 

Aim 2. Robustly predict causative mutations from DNA variants and CFPS. I will lead research that will aid genetic diagnoses with CFPS. The collective body of work to bring CFPS and DNA variant data together is essential for CFPS to become ready for clinical genetic data. To do this I will create family representations to differentiate between de novo and inherited phenotype. With a vector representation of a face during development CFPS will be able to capture and predict disease progression. I will also put in place a robust statistical framework to infer causative DNA variants in rare de novo mutation diseases to empower the search for ultra-rare syndromes. 

Aim 3. Develop the big data framework for implementing CFPS in global healthcare. Current ethical, law and data security concerns are a major hurdle in the path of bringing CFPS to patients. Within the scope of this Fellowship I will address each of these challenges. Patient images through collaborations and patient contributions will involve applying for REC approval to ask for consent and for people to contribute photos from their family albums. This will be both an exercise in public engagement but also en masse data collection. I will be working with ethics, law and eHealth data management questions to enable CFPS to develop into a form which will be not only powerful, but also usable in clinical settings.</gtr:technicalSummary><gtr:potentialImpactText>This project is highly collaborative both within the UK and internationally. This is also translational and interdisciplinary science, criss-crossing the fields of computer vision, computational biology, and clinical genetics. Consequently it provides several direct pathways to impact. The most important of these is that my work will aid in the clinical diagnosis worldwide of the genetics of rare disorders. I have established and will be expanding an international network of collaborations to apply and develop our approach using patient data. I expect this project in 4 years' time to have progressed to being in the early stages of implementation in clinical genetics counselling, initially in the UK and Europe and then elsewhere. 

In the space of three years the following directions will lead to measurable impacts:

The methods to interrogate CFPS together with genotype will add statistical power to the inference of genetic diagnoses. In collaboration with clinical sequencing efforts our approach will be applied to patient image data to add value to these existing datasets and on-going projects. This will result in research participants receiving diagnoses that otherwise they would not. 

I will set up partnerships with patient support groups for syndromes with identified genetic origins. This will be a means to present the science and the project to directly engage the public, and offer the opportunity to contribute photos (under a REC approved informed consent model) for the further refinement of the CFPS. This is public engagement of the best and most interactive kind, which can be measured by the number of images of individuals (&amp;gt;10,000) and syndromes (&amp;gt;200) that I aim to collect over the coming 4 years.

Collaborations will be expanded to additional clinical geneticists across the world. For clinicians the practical utility would be to evaluate the approach as a means of narrowing down hypotheses for the clinical diagnosis of known syndromes. As the work to interrogate DNA variant data together with CFPS develops we will be able to narrow the search for causative variants in patient data even where no established diagnosis exists. Results will also directly feed back to the project, as they will expand the number of images of clinically defined syndromes that will iteratively improve the CFPS - the more people that use it the better it gets. 

Extending contacts within the MRC Units in The Gambia and Uganda would be a beneficial means of geographically widening our research to efficiently test and apply CFPS in the future. At the end of the 4 year Fellowship CFPS will be ready for testing and accreditation for use in the NHS and be ready to begin testing in clinics in more countries around the world. With care during the methodological development of the CFPS this should be achievable on a large scale rapidly.</gtr:potentialImpactText><gtr:fund><gtr:end>2019-06-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2015-07-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>457586</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Great Ormond Street Hospital (GOSH)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Minerva Consortium</gtr:description><gtr:id>50D6548E-F40E-46B5-86AB-D1A7BE3CF28D</gtr:id><gtr:impact>Newly launched, no outputs yet.</gtr:impact><gtr:outcomeId>58b456d02bc868.23576607-8</gtr:outcomeId><gtr:partnerContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:partnerContribution><gtr:piContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Radboud University Nijmegen Medical Center</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>Minerva Consortium</gtr:description><gtr:id>20E28C67-4615-4567-A9B9-83FD1B0B4581</gtr:id><gtr:impact>Newly launched, no outputs yet.</gtr:impact><gtr:outcomeId>58b456d02bc868.23576607-1</gtr:outcomeId><gtr:partnerContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:partnerContribution><gtr:piContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King Edward Memorial Hospital</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:description>Minerva Consortium</gtr:description><gtr:id>979F88F6-36D4-40DC-AE55-B928D6CF58BD</gtr:id><gtr:impact>Newly launched, no outputs yet.</gtr:impact><gtr:outcomeId>58b456d02bc868.23576607-14</gtr:outcomeId><gtr:partnerContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:partnerContribution><gtr:piContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Charles University</gtr:collaboratingOrganisation><gtr:country>Czech Republic</gtr:country><gtr:department>School of Medicine Charles Prague</gtr:department><gtr:description>Minerva Consortium</gtr:description><gtr:id>84342F6F-20E5-46BF-9EA5-7CD90CBEE079</gtr:id><gtr:impact>Newly launched, no outputs yet.</gtr:impact><gtr:outcomeId>58b456d02bc868.23576607-13</gtr:outcomeId><gtr:partnerContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:partnerContribution><gtr:piContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Freeman Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Minerva Consortium</gtr:description><gtr:id>9606A5E5-84A7-429A-84E4-2B9E679B4743</gtr:id><gtr:impact>Newly launched, no outputs yet.</gtr:impact><gtr:outcomeId>58b456d02bc868.23576607-15</gtr:outcomeId><gtr:partnerContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:partnerContribution><gtr:piContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cape Town</gtr:collaboratingOrganisation><gtr:country>South Africa, Republic of</gtr:country><gtr:description>Minerva Consortium</gtr:description><gtr:id>87B0DE9C-2B9A-4D58-B460-90259E793DD6</gtr:id><gtr:impact>Newly launched, no outputs yet.</gtr:impact><gtr:outcomeId>58b456d02bc868.23576607-17</gtr:outcomeId><gtr:partnerContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:partnerContribution><gtr:piContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imagine Institute</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>Minerva Consortium</gtr:description><gtr:id>AE183DBB-7AE2-4465-8F46-6042A514472D</gtr:id><gtr:impact>Newly launched, no outputs yet.</gtr:impact><gtr:outcomeId>58b456d02bc868.23576607-11</gtr:outcomeId><gtr:partnerContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:partnerContribution><gtr:piContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Cambridge Institute for Medical Research (CIMR)</gtr:department><gtr:description>Minerva Consortium</gtr:description><gtr:id>8478F3C5-29C0-4F89-968F-FBABF822CD94</gtr:id><gtr:impact>Newly launched, no outputs yet.</gtr:impact><gtr:outcomeId>58b456d02bc868.23576607-21</gtr:outcomeId><gtr:partnerContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:partnerContribution><gtr:piContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Weatherall Institute of Molecular Medicine (WIMM)</gtr:department><gtr:description>Minerva Consortium</gtr:description><gtr:id>C11CB127-44D7-44E7-A2B1-35C184B6A953</gtr:id><gtr:impact>Newly launched, no outputs yet.</gtr:impact><gtr:outcomeId>58b456d02bc868.23576607-2</gtr:outcomeId><gtr:partnerContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:partnerContribution><gtr:piContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Jackson Laboratory</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Minerva Consortium</gtr:description><gtr:id>45F91E50-B2FD-4D09-A4BC-847520E81348</gtr:id><gtr:impact>Newly launched, no outputs yet.</gtr:impact><gtr:outcomeId>58b456d02bc868.23576607-5</gtr:outcomeId><gtr:partnerContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:partnerContribution><gtr:piContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Washington</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Minerva Consortium</gtr:description><gtr:id>8E0B2C25-BFE6-41CD-85ED-4845161D7705</gtr:id><gtr:impact>Newly launched, no outputs yet.</gtr:impact><gtr:outcomeId>58b456d02bc868.23576607-20</gtr:outcomeId><gtr:partnerContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:partnerContribution><gtr:piContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Melbourne</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:department>Murdoch Children's Research Centre</gtr:department><gtr:description>Minerva Consortium</gtr:description><gtr:id>FF2AEEFD-2CC4-48F2-8324-E9EA40507F6E</gtr:id><gtr:impact>Newly launched, no outputs yet.</gtr:impact><gtr:outcomeId>58b456d02bc868.23576607-9</gtr:outcomeId><gtr:partnerContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:partnerContribution><gtr:piContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Hospital for Sick Children, Toronto</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>Minerva Consortium</gtr:description><gtr:id>128E2412-EDE3-49E5-9294-80EFFEADE873</gtr:id><gtr:impact>Newly launched, no outputs yet.</gtr:impact><gtr:outcomeId>58b456d02bc868.23576607-10</gtr:outcomeId><gtr:partnerContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:partnerContribution><gtr:piContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Charit? - University of Medicine Berlin</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>Minerva Consortium</gtr:description><gtr:id>74858986-0C88-48F6-A8F1-2FE3E48E8243</gtr:id><gtr:impact>Newly launched, no outputs yet.</gtr:impact><gtr:outcomeId>58b456d02bc868.23576607-3</gtr:outcomeId><gtr:partnerContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:partnerContribution><gtr:piContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Garvan Institute for Medical Research</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:description>Minerva Consortium</gtr:description><gtr:id>55B281A0-61EA-4148-B250-6E4DE39602AC</gtr:id><gtr:impact>Newly launched, no outputs yet.</gtr:impact><gtr:outcomeId>58b456d02bc868.23576607-19</gtr:outcomeId><gtr:partnerContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:partnerContribution><gtr:piContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Baylor College of Medicine</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Minerva Consortium</gtr:description><gtr:id>B4C9795E-2B5D-4A53-A59A-1DF89AD8FE27</gtr:id><gtr:impact>Newly launched, no outputs yet.</gtr:impact><gtr:outcomeId>58b456d02bc868.23576607-4</gtr:outcomeId><gtr:partnerContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:partnerContribution><gtr:piContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Manchester University NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Minerva Consortium</gtr:description><gtr:id>951ECE4B-5670-4346-B978-00B80768723A</gtr:id><gtr:impact>Newly launched, no outputs yet.</gtr:impact><gtr:outcomeId>58b456d02bc868.23576607-12</gtr:outcomeId><gtr:partnerContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:partnerContribution><gtr:piContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Oregon Health and Science University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Minerva Consortium</gtr:description><gtr:id>F83E7503-CD47-468A-AF4B-D5059FFE6EA0</gtr:id><gtr:impact>Newly launched, no outputs yet.</gtr:impact><gtr:outcomeId>58b456d02bc868.23576607-16</gtr:outcomeId><gtr:partnerContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:partnerContribution><gtr:piContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Minerva Consortium</gtr:description><gtr:id>EC350FDF-3628-4DAC-B15C-BAA56DDE6623</gtr:id><gtr:impact>Newly launched, no outputs yet.</gtr:impact><gtr:outcomeId>58b456d02bc868.23576607-18</gtr:outcomeId><gtr:partnerContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:partnerContribution><gtr:piContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Wellcome Trust Sanger Institute</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Minerva Consortium</gtr:description><gtr:id>4C9D89BF-A11D-40CC-8940-0840A64103B8</gtr:id><gtr:impact>Newly launched, no outputs yet.</gtr:impact><gtr:outcomeId>58b456d02bc868.23576607-6</gtr:outcomeId><gtr:partnerContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:partnerContribution><gtr:piContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Media engagement around eLIFE publication</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>112F7460-8B49-4779-999F-08A82C3E869B</gtr:id><gtr:impact>More than 5 new potential collaborations around the world were initiated as a direct result of media covering the publication of our article in eLIFE. 
A number of parents of patients contacted us directly for more information.


Three keynote invitations to present at scientific conferences were offered after the media attention.
New collaborations with clinicians and scientists around the world have been started.</gtr:impact><gtr:outcomeId>5436808d8b89e1.86952146</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>https://www.obs-gyn.ox.ac.uk/team/christoffer-nellaker</gtr:url><gtr:year>2014,2015,2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>404250</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Methodology Research Grant</gtr:description><gtr:end>2019-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/M01326X/1</gtr:fundingRef><gtr:id>AA173A34-4904-4C75-A5F7-14A495680860</gtr:id><gtr:outcomeId>56b9fb81160090.32944092</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Invited presented to APPG - 'How does data-sharing support global health and policy'?</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>480771A2-68C0-49A1-B941-2C63CFC10690</gtr:id><gtr:outcomeId>58988798f1cd46.98794854</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>BF3F5EC2-E2DA-47C6-83FD-12AFE0F4D744</gtr:id><gtr:title>Prevalence and architecture of de novo mutations in developmental disorders.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3fd4d480801d072e0ab142663a0736f4"><gtr:id>3fd4d480801d072e0ab142663a0736f4</gtr:id><gtr:otherNames>Deciphering Developmental Disorders Study</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>589880e5673c56.33497113</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7B7E024F-B0D8-456B-A4E6-4DD83578CF99</gtr:id><gtr:title>PURA syndrome: clinical delineation and genotype-phenotype study in 32 individuals with review of published literature.</gtr:title><gtr:parentPublicationTitle>Journal of medical genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d372eb68216ce4d7e257db6d0cc4b553"><gtr:id>d372eb68216ce4d7e257db6d0cc4b553</gtr:id><gtr:otherNames>Reijnders MRF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0022-2593</gtr:issn><gtr:outcomeId>5a93e831698992.37753514</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2293B5E6-D497-4B5A-AB6A-8D6A7132FD33</gtr:id><gtr:title>Clinical and molecular consequences of disease-associated de novo mutations in SATB2.</gtr:title><gtr:parentPublicationTitle>Genetics in medicine : official journal of the American College of Medical Genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/05839e074e7c4e7051cc77c710f184f4"><gtr:id>05839e074e7c4e7051cc77c710f184f4</gtr:id><gtr:otherNames>Bengani H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1098-3600</gtr:issn><gtr:outcomeId>589880e597b701.12631172</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/M014568/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>